Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution
30.6.2026 17:00:00 CEST | Business Wire | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability.
The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most.
Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border programs while providing a more connected path from First-in-Human studies, both in healthy volunteers and patients, through registration.
The result is broader capabilities, deeper expertise, and greater continuity - delivered with the responsiveness, accountability, and close collaboration that clients expect from a specialist CRO.
With long-established operations across Europe and nearly five decades of experience supporting innovative biopharma companies, Simbec-Orion has built a reputation for helping sponsors navigate some of the industry's most complex development challenges. The organization brings specialized expertise in clinical pharmacology, oncology and rare disease, spanning Phase I through Phase III trials, supported by a strong European footprint and trusted relationships across the biotech ecosystem. The combination includes Simbec-Orion's 48-bed Phase I clinical pharmacology unit, one of Europe's leading early-phase facilities, giving sponsors a continuous path from First-in-Human studies through registration that preserves knowledge, accountability, and momentum at every stage.
“We are thrilled to bring together the Simbec-Orion and Caidya teams,” said Barbara Lopez Kunz, Chief Executive Officer of Caidya. “This strategic combination brings together complementary strengths to create a more complete development partner for innovators. By combining Simbec-Orion’s European presence and early-phase expertise with Caidya’s global platform, we can support sponsors from First-in-Human through registration while helping them thrive where development becomes most difficult: at the intersection of scientific innovation, operational complexity, and global clinical execution.”
“We are pleased to be joining forces with Caidya – which shares so much of our common culture,” said Fabrice Chartier, Chief Executive Officer of Simbec-Orion. “Our combined organization creates a CRO that combines the intimacy of a specialist partner with the reach of a global development organization to meet the needs of modern drug development. Together, we will enhance our combined geographic footprint, benefiting Simbec-Orion with enhanced access to the U.S. and Asian markets, and Caidya with greater presence in Europe and in Phase I clinical pharmacology. We are extremely excited to partner with Caidya to create a more complete partner for innovators.”
“Simbec-Orion has built a reputation for excellence in clinical research, particularly in navigating the complexities of early-phase development and European regulatory environments,” said Dr. Lingshi Tan, Executive Chairman of the Board at Caidya. “By integrating their expertise with Caidya’s global reach and deep therapeutic experience, we are uniquely positioned to support the growing trend of cross-border biopharma innovation, particularly the dual-direction flow of therapies among the U.S., Europe, and Asia.”
“CBPE has been proud to support significant investment in people and the digital transformation of Simbec-Orion, enabling strong growth since 2019. We are confident that joining forces with Caidya represents the ideal next chapter for the business, its people, and its clients,” said Anand Jain, Partner at CBPE and Chairman of Simbec-Orion. “By combining aligned cultures with a more connected development model, sponsors gain a continuous path from First-in-Human through to registration without changing the experienced partner they trust.”
With complementary cultures and a shared commitment to focus, speed, and accountability, the combined organization will operate under the leadership of Barbara Lopez Kunz as CEO, with Fabrice Chartier continuing to lead Simbec-Orion's operations as part of the combined company. With a strategic footprint spanning key global markets, Caidya continues its mission to partner with drug developers to bring life-changing therapies to patients worldwide.
Edgemont acted as exclusive financial advisor to Caidya, and Sidley Austin served as legal counsel to Caidya. Stifel acted as financial advisor and Eversheds Sutherland served as legal counsel to Simbec-Orion and CBPE.
For more information about Caidya and its services, please visit www.caidya.com.
About Caidya
Caidya is a global CRO partner dedicated to helping biopharma innovators navigate the complexities of drug development with greater speed, certainty, and confidence. We specialize in the execution of complex clinical trials, including challenging therapeutic areas, innovative study designs, rare patient populations, and cross-border programs. We partner closely with sponsors to advance breakthrough therapies for patients with unmet medical needs worldwide.
With a strategic footprint across the Americas, Europe, and Asia-Pacific, including deep expertise in China, Caidya combines global reach with local knowledge to support regional and global studies. We work as an extension of our clients to overcome complexity, reduce risk, and generate the high-quality data needed to advance critical therapies.
About Simbec-Orion
Headquartered in the UK, Simbec-Orion is an experienced, technology-enabled, global Contract Research Organisation (CRO) specialising in clinical pharmacology, oncology, and rare diseases. With over five decades of experience, Simbec-Orion provides clinical trial expertise to a wide range of small to mid-sized biotech and pharmaceutical partners around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260630863968/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
90% of IT Leaders See Gaps in AI Threat Readiness, Lenovo Brings Single Point of Accountability to Cyber Resiliency30.6.2026 15:00:00 CEST | Press release
New end-to-end resilience and managed security offerings help organizations reduce security complexity, cut system downtime by up to 50%, and lower remediation costs by up to 40% by bringing devices, security technologies, expert services, and ecosystem partners together under a single operational model As organizations accelerate AI adoption and digital workplace transformation, many are finding that cyber resilience is undermined not by a lack of security tools, but by growing operational complexity and threat sophistication. According to recent research, 90% of IT leaders acknowledge gaps in their ability to defend against AI-driven threats. While security investments continue to grow, many organizations face a different challenge: fragmented accountability. Security operations remain highly distributed and siloed, making it increasingly difficult to coordinate response efforts, maintain end-to-end business continuity, and recover quickly when incidents occur. To help organizations
Tacton Launches Portfolio Performance Intelligence to Help Manufacturers Understand Why Products Win30.6.2026 15:00:00 CEST | Press release
New configuration-aware commercial intelligence capability connects customer requirements, configuration decisions, and business outcomes to optimize win rates, margin and product strategy. Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the launch of Portfolio Performance Intelligence, a new analytics capability designed to help manufacturers understand why products win, where margin is created or lost, and which decisions consistently drive successful business outcomes. Manufacturers don't lack data. They lack the context needed to understand why products perform the way they do and why customers choose them. ERP systems show what was sold, CRM platforms track opportunities, and BI tools visualize trends. But when manufacturers try to understand which customer requirements drive demand, which configurations consistently win, or why margins vary across products, regions or segments, the answers are often unclear
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom